1 TITLE PAGE

2

3	Excess weight increases the risk for neurological and neuropsychiatric symptoms in
4	post-COVID-19 condition: A systematic review and meta-analysis
5	Short title: Excess weight increases Post-COVID-19 Condition neuro-symptoms
6	
7	Débora Barbosa Ronca ^{1,2¶*,#a} , Larissa Otaviano Mesquita ^{1,&} , Dryelle Oliveira ³ , Ana
8	Cláudia Morais Godoy Figueiredo ^{2,4,&} , Jun Wen ⁵ , Manshu Song ⁶ , Kênia Mara Baiocchi
9	de Carvalho ^{1,3} ¶
10	¹ Graduate Program of Public Health, Faculty of Health Sciences, University of Brasília;
11	Brasília, Federal District, Brazil.
12	² Health Department of Federal District, Brasília, Federal District, Brazil.
13	³ Graduate Program of Human Nutrition, Faculty of Health Sciences, University of
14	Brasília, Brasília, Federal District, Brazil.
15	⁴ Superior School of Health Sciences, Brasília, Federal District, Brazil.
16	⁵ Faculty of Hospitality and Tourism Management, Macau University of Science and
17	Technology, Macau SAR, China.
18	⁶ School of Medical and Health Sciences, Edith Cowan University, Perth, Western
19	Australia, Australia.
20	${}^{\#\!a} Current address: School of Medical and Health Sciences, Edith Cowan University, Perth,$
21	Western Australia, Australia.
22	
23	Corresponding authors: Débora Barbosa Ronca. E-mail: d.ronca@ecu.edu.au /
24	deboraronca@gmail.com (DBR)
25	Co-corresponding authors: Kênia Mara Baiocchi de Carvalho. E-mail:kenia@unb.br
26	(KMBC); Manshu Song. E-mail: m.song@ecu.edu.au (MS)

28 Abstract

29 Background/purpose: Excess weight has been identified as a potential risk factor for the 30 development of post-COVID-19 condition (PCC). This review investigates whether 31 excess weight increases the risk of neurological and neuropsychiatric symptoms 32 associated with PCC. Methods: Studies published up to July 2023 were searched 33 independently across eight electronic databases to evaluate the risk of developing 34 neurological and neuropsychiatric symptoms more than 12 weeks post-infection between 35 exposure and controls groups (excess weight vs. normal weight; obesity vs. non-obesity). 36 Meta-analyses were conducted under a random-effects model. Results: Of the 10,122 37 abstracts screened, 18 studies (n = 139,091 adults) met the inclusion criteria and reported 38 PCC symptoms according to nutritional status. These studies included 79.050 individuals 39 with excess weight vs 57,926 normal-weight individuals and 30,694 individuals with 40 obesity vs 107.612 non-obese individuals. The presence of excess weight in PCC 41 significantly increased the risk of depression (RR = 1.21; 95% CI: 1.03–1.42), headache 42 (RR = 1.21; 95% CI: 1.09–1.35), memory issues (RR = 1.43; 95% CI: 1.24–1.65), sleep 43 disturbance (RR = 1.31; 95% CI: 1.16–1.48), and vertigo (RR = 1.21; 95% CI: 1.04– 44 1.41). Obesity significantly increased the risk of headache (RR = 1.41; 95% CI: 1.34– 45 1.49), smell disorder (RR = 1.15; 95% CI: 1.09–1.21), taste disorder (RR = 1.21; 95% CI: 46 1.07-1.36), and vertigo (RR = 1.44; 95% CI: 1.35-1.53). Conclusions: Excess weight or 47 obesity increases the risk of experiencing neuro-symptoms related to PCC. Individuals 48 with these conditions urgently need enhanced personalized care management in current 49 post-pandemic context.

50 Keywords: Post-COVID-19 condition, Neurological symptoms, Neuropsychiatric
 51 symptoms, Obesity, Systematic review

54 Introduction

55 A growing body of evidence suggests that a subset of COVID-19 survivors 56 develop persistent, debilitating symptoms and may face a long road to complete 57 recovery[1–4]. These symptoms have been shown to affect multiple organ systems, as 58 evidenced by respiratory, cardiovascular, neurological, and mental health manifestations. 59 This emergent condition has several names: long-COVID; post-acute sequelae of SARS-60 CoV-2 syndrome; and, as per the World Health Organization (WHO), post-COVID-19 61 condition (PCC). Although PCC has no uniform definition in the literature, it is generally 62 described as involving persistent symptoms or new symptom onset, typically 12 weeks from the acute phase of COVID-19[5, 6], presenting a novel challenge to healthcare 63 64 systems[7].

65 To date, no comprehensive effective treatment has been recognized for PCC, and 66 the common strategies are based on symptoms relief[8]. Among PCC's range of 67 symptoms, long-term COVID-19 neurological and neuropsychiatric manifestations are of 68 particular interest given the higher incidence of nervous system related sequalae's after 69 post-viral epidemics[9]. Prior reviews revealed that smell and taste disorders, headache, 70 sleep disturbance, anxiety and depression were among the most commonly reported 71 persistent symptoms in the general population. However, these studies only follow 72 participants for a few weeks post-COVID infection and do not meet the criteria for 73 PCC[10–13]. The severity of the COVID-19 acute phase has been associated with the 74 development of long-term COVID-19 neuropsychiatric symptoms[14]. The body mass 75 index (BMI) has been regarded as a potential risk factor for PCC, although the association 76 of excess weight (EW) with the development of specific neurological and 77 neuropsychiatric symptoms remains unclear [15, 16]. Moreover, studies that reported the 78 prevalence of persistent neurological and neuropsychiatric symptoms up to one year after

COVID-19 onset exhibited considerable heterogeneity and did not perform subgroups
analyses according to nutritional status[2, 17]. An increased number of PCC symptoms
that longer persist may be experienced by individuals with EW and might be associated
to worsen health and poor quality of life[18].

83 It is noteworthy that EW is a chronic suboptimal heath condition characterized by 84 excessive fat deposits and is considered a global public health problem. It represents a 85 major risk factor for other chronic conditions and encompasses overweight, a suboptimal 86 body weight that represents a risk to health, and obesity, a metabolic disease[19, 20]. A 87 complex yet costly care of individuals with EW is required, with appropriate 88 multidisciplinary, long-term support[19]. In 2020, the overweight and obesity pandemic 89 collided with the COVID-19 pandemic. These conditions' joint negative effects have increased the incidence of related diseases, leading to potentially adverse clinical and 90 91 social consequences[21-23]. Obesity was found to be associated with poor COVID-19 92 outcomes, such as hospital admissions, intensive care admissions, and lethality rates[24-93 26]. Although the COVID-19 pandemic has come under control, the multisystemic nature 94 of this disease and its long-term impacts have yet to be elucidated [10, 27].

95 Although there is literature on the most commonly reported neurological and 96 neuropsychiatric symptoms of PCC, few studies reported the risk of PCC symptoms 97 according to nutritional status and no previous review has explored the association of EW 98 and the risk of developing specific neurological or neuropsychiatric symptoms among 99 COVID-19 survivors. Elucidating the long-term neuro-outcomes of COVID-19, along 100 with its suite of symptoms and high-risk populations, is urgently needed to facilitate the 101 development of reliable and personalized care management strategies. Therefore, this 102 systematic review addresses whether EW increases the risk of developing specific 103 persistent neurological or neuropsychiatric symptoms among COVID-19 survivors.

104 Materials and Methods

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines[28]. It is a subset of broad research aimed at investigating the role of EW in the development of persistent symptoms of PCC. This review was registered at the International Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42023433234).

110 Search strategy and Eligibility Criteria

111 Two authors (DBR and LOM) searched seven electronic databases (MEDLINE, 112 EMBASE, SCOPUS, Web of Science, VHL, Google Scholar, ProQuest) and a preprint 113 server (medRxiv) on 3 July 2023. The search strategy was reviewed by two reviewers 114 according to the criteria of the Peer Review of Electronic Search Strategies (PRESS) 115 checklist[29]. The search strategy included the following terms: ("long COVID-19" OR 116 "post-acute covid 19 syndrome" OR "COVID-19" OR "SARS-CoV-2" OR "post-117 COVID-19 condition" OR "long hauler") AND ("excess of weight" OR "overweight" 118 OR "obesity" OR "body mass index") AND ("signs and symptoms" OR "COVID-19 119 sequelae" OR "headache" OR "loss of smell" OR "cognitive dysfunction" OR "anxiety" 120 OR "depression" OR "sleep disorder" OR "brain fog)." The full search strategy is detailed 121 in supporting information (S1 Table). Additionally, some articles were hand-searched to 122 identify potentially eligible studies which might not be electronically retrieved, including 123 those published in 2024.

124 Studies were considered eligible for inclusion if they (a) had observational 125 designs; (b) primarily focused on adults; (c) classified focal populations based on the 126 presence of excess weight/obesity *versus* normal weight/non-obesity, using either 127 measured BMI or self-reported data; and (d) had a mean (or median) follow-up of at least 128 12 weeks after the acute phase of COVID-19. Survivors could be (a) hospitalized or non-

hospitalized, (b) inpatient or outpatient, and (c) mixed population (hospitalized andoutpatient) recruited in the community, outpatient clinic or heath care system.

131 We exclude editorials, clinical trials, reviews, opinions, books or book chapters, 132 conference abstracts, case reports, and correspondence articles. Studies were also 133 excluded if they included mostly pregnant or nursing women; evaluated the health effects 134 of COVID-19: assessed excess weight as a risk factor for acute-phase severity or 135 mortality; or evaluated long-term sequelae of COVID-19 in a specific population (e.g., 136 individuals with specific comorbidities). Additionally, studies were excluded if they 137 investigated clusters of symptoms rather than specific symptoms or if they lacked a 138 control group (i.e., COVID-19 survivors who did not report persistent symptoms).

139 Screening Process, Study Selection, and Data Extraction

The same two authors (DBR and LOM) independently screened the titles and abstracts of studies obtained from database searches and removed duplicates. The Rayyan app[30], a semi-automation tool, was used to streamline the review process. This was followed by a full-text review of the retained articles to ensure they met eligibility criteria. Fig 1 presents the flowchart for the included studies.

145

146 **Fig 1: Flow diagram of included studies.**

147

The study population of interest comprised COVID-19 survivors. Exposure was defined as EW or obesity based on BMI measurement, data from electronic medical records, or self-reported information. Two exposure groups were defined according to WHO guidelines[31]: 1) an excess weight group (BMI \geq 25 kg/m²) and 2) an obesity group (BMI \geq 30 kg/m²). Both Asian and Caucasian populations were included in the analysis, with corresponding BMI cut-offs applied: for Asian-Pacific populations, the

thresholds were BMI \geq 23 kg/m² for EW and BMI \geq 25 kg/m² for obesity, as previously defined in the included studies[32, 33].

156 We adopted WHO's definition of PCC as outlined by Soriano et al. (2021)[5]. 157 Symptoms were measured with predefined questionnaires/scales or reported during 158 interviews (in person, by phone, or online). Due to varying definitions illness onset 159 (baseline), we accepted definitions that included 12 weeks from the onset of COVID-19 160 symptoms, COVID-19 diagnosis, hospital admission or discharge after the acute phase. 161 For the follow-up period, we considered studies where the sample median (or mean) of 162 persistent symptoms was reported at least 12 weeks (84 days) after the baseline, with a 163 minimum interguartile range (IQR) of 10 weeks (or a standard deviation (SD) of ± 24 164 days) from baseline. This cut-off was necessary to include studies evaluating long-term 165 sequelae of COVID-19. Given the varied terminology used for symptoms across studies, 166 we re-grouped symptoms into neurological and neuropsychiatric categories as shown in 167 Fig 2.

107

168

169 Fig 2: Reported neurological and neuropsychiatric symptoms related to Post-

170 COVID-19 condition (PCC). ^a Neurological and neuropsychiatric reported symptoms were grouped
171 into one category with synonyms presented in brackets.

172

173 Specific data were exported from each study into a predefined data collection 174 form, including authors; publication year; country; aim of the study; study design; mean 175 follow-up period; study population; exposure groups; assessment of outcome; evaluated 176 symptoms; frequency of symptoms (n, %) among exposure and control groups; and the 177 effect measure of the association of EW and the neurological/neuropsychiatric symptom. 178 Corresponding authors of relevant articles published were contacted if any data were 179 absent.

180 Quality Assessment

181 The ROBINS-E tool for observational research was used to determine the risk of 182 bias in the included studies[34]. ROBINS-E is a domain-based tool that evaluates seven 183 domains (confounders, exposure measurement, participant selection, post-exposure 184 interventions, missing data, outcome measurement, and selection of reported results) and 185 then a general assessment of the study. Traffic plots with a final analysis of studies' risk 186 of bias, by domain, is generated. For this research, two authors (DBR and DO) initially 187 appraised the risk of bias. Disagreements were discussed and resolved in collaboration 188 with a third researcher (LOM). The ROBINS-E tool was not applied as a study eligibility 189 criterion.

We assessed the certainty of evidence via the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework [35–37] regarding the risk of developing PCC-related neurological and neuropsychiatric symptoms among individuals with EW. The GRADE system measures attributes that impact the overall quality of evidence. We assessed the certainty of evidence of the outcomes that were statistically significantly associated with exposures groups and scored it accordingly (i.e., high = \geq 4 points; moderate = 3 points; low = 2 points; very low = 1 point).

197 Statistical Analysis

The frequency of reported symptoms and the associated risk of development were determined for EW *vs* normal weight groups and for obesity *vs* non-obesity groups, classified by BMI when available (normal weight: BMI of 18–24.9 kg/m²; excess weight: BMI >25 kg/m²; obesity: BMI >30 kg/m²; non-obesity group: BMI <30 kg/m²), taking into account different cut-off values previously defined for the Chinese population in studies[32, 33]. Each symptom was considered an individual outcome. For this purpose, we collected data of the frequency (*n*, %) of each neurological and neuropsychiatric

symptoms related to PCC reported and the risk of developing persistent symptoms (as
measured by the odds ratio [OR] or the adjusted OR) at follow-up in included studies.

207 We performed meta-analytic calculations using STATA software (SE/17). Pooled 208 risk ratios (RRs) with their 95% confidence intervals (CIs) were computed from the raw 209 data of the included studies. A random effects model meta-analysis was conducted to 210 account for the statistical and methodological heterogeneity of the data. We used a two-211 sample binary-outcome summary dataset format with DerSimonian-Laird estimation 212 when fewer than five studies were available[38]; when more than five studies were 213 available, we adopted restricted maximum-likelihood estimation and to conduct pooled 214 RR analysis. Statistical heterogeneity was assessed using the I^2 statistic[39]. Forest plots 215 were generated for all outcomes. Publication bias was examined by visual inspection of 216 funnel plots. A value of p < 0.05 was considered statistically significant.

217

218 **Results**

Of the 10,122 abstracts screened, 211 full-text registers were reviewed, and 65 studies were considered eligible. Data on neurological and neuropsychiatric symptoms according to individuals' nutritional status were available for 18 studies (including one preprint[40]), all of which were entered into our meta-analysis.

Selected studies originated from 23 countries across Asia (China[32, 33], India[41], Indonesia[42], Japan[43], Malaysia[40] and Saudi Arabia[44]), Europe (Denmark[45, 46], England[47], Germany[48], Italy[49], Poland[50], Spain[51] and Switzerland[52]), and North and South America (Argentina[53], Brazil[53], Chile[53], Dominican Republic[53], Ecuador[53], Mexico[53], Panama[53], Paraguay[53], Peru[53] and United States of America[54, 55]), comprising both developed and developing countries. Among the included studies, two employed case–control design[51,

54], six involved retrospective or prospective cohorts[33, 42, 49, 50, 52, 55], and 10

231 involved cross-sectional studies[32, 40, 41, 44–47, 47, 48, 53].

232 The populations investigated varied: three studies evaluated individuals in 233 outpatient settings [46, 52, 54], five involved hospitalized patients [32, 33, 42, 49, 51], 234 and ten included individuals either hospitalized or outpatient settings during COVID-19 235 acute-phase[40, 41, 43, 44, 47, 48, 50, 53, 55]. The classification of individuals according 236 to nutritional status also varied: four studies compared symptoms between individuals 237 with EW and those with normal weight[32, 40, 42, 44], five studies evaluated obesity 238 versus non-obesity[33, 48–51], eight studies presented data for individuals with normal 239 weight, overweight and obesity[41, 45–47, 52–55], and one study only provided the mean 240 BMI of the sample without specifying the number of individuals in exposure and control groups[43]. In total, our meta-analysis included 79,050 people with EW and 30,694 with 241 242 obesity in exposure groups, while 57,926 normal weight individuals and 107,612 non-243 obese individuals comprised control groups. Sample sizes ranged from 32[54] to 244 78,566[47] COVID-19 survivors. Two Chinese studies applied different cut-off points for 245 nutritional status classification (EW as BMI $\geq 23 \text{ kg/m}^2$; obesity as BMI $\geq 25 \text{ kg/m}^2$)[32, 246 33]. Exposure was assessed via anthropometric measures[32, 33, 41, 50, 53, 54], 247 electronic medical record data[42, 46, 49, 51], and self-reported comorbidity/BMI[40, 248 43-45, 47, 52, 55]. PCC neurological and neuropsychiatric symptoms were evaluated 249 using questionnaires[33, 41, 43–47, 50–52, 54], validated scales[32, 40, 48, 49, 51, 54], 250 or self-report instruments[42, 47, 48, 53, 55]. The mean time from COVID-19 onset 251 (baseline) to long-term symptom assessment was 25.8 weeks (range: 12 weeks[42, 44, 252 46, 47, 49] to 52 weeks [one year][32]). Table 1 outlines the features of the included 253 articles.

Table 1. Characteristics of included studies.

Author, Year	Country	Study aim	Study design; Follow-upª	Study population	Categories of nutritional status	Assessment type	Main neurological (N) and neuropsychiatric (NP) symptoms evaluated
Alkwai, H.M. <i>et al.,</i> 2022 [44]	Saudi Arabia	To analyze the persistence of COVID-19 symptoms and return	Cross- sectional; 12 weeks after	Mixed population ^b n = 108 (male = 23)	Overweight $(n = 32)$ Normal weight	Online survey Self-reported comorbidities	N: Concentration issues, headache, memory issues, numbness, smell disorder, taste disorder, vertigo
		to the usual state of health	COVID-19 infection	Age range: 18–65 years	(n = 181)	Symptom questionnaire	NP: mood change, sleep disturbance
Blümel, J.E. <i>et al.</i> , 2022 [53]	Nine Latin- American countries ^c	To study the development of long- term symptoms and the impacts of COVID-19 on mental health and quality of life in middle-aged women	Cross- sectional; 32 weeks after COVID-19 infection	Mixed population ^b Sample of interest / study sample n = 304/1,238 (female only) Age: 53.0 (range: 40–64 years)	Obesity $(n = 41)$ Overweight (n = 124) Normal weight (n = 139)	In-person interview Measured BMI Reported symptoms	N: anorexia, cognitive deficit, headache, memory issues, numbness, smell disorder, taste disorder, vertigo NP: anxiety, sleep disturbance
Bungenberg, J. <i>et al.</i> , 2022 [48]	Germany	To identify and compare persistent self-reported symptoms in initially hospitalized and non- hospitalized patients after infection	Cross- sectional; 13.4 weeks for non-hosp. and 41 weeks for hosp. patients after acute symptoms	Mixed population ^b n = 50 (male = 22) Age: 50.5 (range: 40–64 years)	Obesity $(n = 7)$ Non-obesity (n = 43)	In-person interview Reported symptoms and scales	N: cognitive deficit, memory issues, smell disorder, taste disorder, vertigo NP: sleep disturbance

Author, Year	Country	Study aim	Study design; Follow-up ^a	Study population	Categories of nutritional status	Assessment type	Main neurological (N) and neuropsychiatric (NP) symptoms evaluated
Carter, S.J. <i>et al.</i> , 2022	United States of	To compare functional status, mood state, and physical activity in	Case–control; 12.1 weeks	Outpatient n = 32 woman SARS-CoV-2	Obesity $(n = 4)$ Overweight $(n = 6)$	In-person interview Measured BMI	N: Cognitive deficit, headache, memory issues,
[54]	America	leisure time among positive COVID-19 and controls	after COVID- 19 diagnosis	group = 17 Age: 55 ± 11 years	Normal weight $(n = 7)$	Questionnaire and Profile of Mood States	smell disorder, taste disorder
Chudzik, M. et al., 2022	Poland	To analyse the prevalence of self- reported smell and/or	Cohort; 28.8 weeks starting 14	Mixed population ^b n = 2,218 (male = 1,410)	Obesity $(n = 692)$	In-person interview Measured BMI	N: Smell and taste
[50]		taste disorders and to identify risk factors for the disease	days after last COVID-19 symptom	Age: 53.8 ± 13.5 years	Non-obesity $(n = 1,485)$	Health questionnaire	disorders
Desgranges, F. <i>et al.</i> , 2022 [52] Switzer- land		tor more than 3	Cohort; 21.4 weeks after initial consultation	Outpatient Sample of interest / study sample n = 418/507 (male = 157)	Obesity $(n = 72)$ Overweight/obe sity (n = 189)	Electronic medical records Telephone interviews Self-reported BMI	N: Headache, loss of balance, memory issues, numbness, smell disorder, taste disorder
[,_]		identify predictors of persistent symptoms	(IQR: 17.2– 29.1)	Age: 41 (range: 31–54 years)	Healthy weight $(n = 229)$	Survey with predefined symptoms	NP: sleep disturbance
Epsi, N.J. <i>et</i> <i>al.</i> , 2024 [55]	United States of America	To improve the definition of PCC with a data-driven approach to phenotyping.	Cohort 24 weeks post- infection	Mixed population ^b n = 1,988 (male = 1,201)	Obesity $(n = 710)$ Overweight (n = 842) Normal weight (n = 436)	Electronic patient records and self- reported BMI Online survey	N: Smell and taste disorder

Author, Year	Country	Study aim	Study design; Follow-up ^a	Study population	Categories of nutritional status	Assessment type	Main neurological (N) and neuropsychiatric (NP) symptoms evaluated
				Age: 69,5% were between 18-44 years old		Survey with predefined symptoms	
Farhanah, N. <i>et al.</i> , 2022 [42]	Indonesia	To determine persistent symptoms and evaluate quality of life in COVID-19 patients 3 months after discharge	Cohort; 12 weeks after hospital discharge	Hospitalized n = 104 (male = 55) Age: 48.9 (range: 18-65 years)	Excess weight (n = 41) Normal weight (n = 63)	Electronic medical records Telephone interviews Reported symptoms	N: headache, smell disorder, sweating, taste disorder NP: sleep disturbance
Fernández- de- Las- Peñas, C. <i>et</i> <i>al, 2021</i> [51]	Spain	To investigate the association of obesity with long-term post-COVID symptoms in hospitalized COVID-19 survivors	Case-control; 28.8 weeks after hospital discharge	Hospitalized n = 264 (male = 159) Age: 52.0 ± 14.5 years	Obesity $(n = 88)$ Non-obesity $(n = 176)$	Electronic medical records Telephone interviews List of symptoms Hospital Anxiety and Depression Scale, Pittsburgh Sleep Quality Index (PSQI)	N: Concentration issues, cognitive deficit, headache, memory issues, numbness, sleep disturbance, smell and taste disorders NP: anxiety, depression
Gaur, R. <i>et</i> <i>al.</i> , 2022 [41]	India	To assess the extent of disability following COVID- 19 infection	Cross- sectional; 15.5 weeks after COVID- 19 infection	Mixed population ^b n = 97 (male = 61) Age: 48.7 ± 15.6 years	Obesity $(n = 32)$ Overweight $(n = 27)$ Normal weight $(n = 38)$	In-person interview Measured BMI Questionnaire	N: Headache, vertigo NP: Sleep disturbance
Li, Z. <i>et al.</i> , 2023 ^d [32]	China	To investigate the mental health status of COVID-19	Cross- sectional;	Hospitalized n = 535 (male = 216)		Self-reported survey Measured BMI	N: Anxiety, depression NP: Sleep disturbance

Author, Year	Country	Study aim	Study design; Follow-up ^a	Study population	Categories of nutritional status	Assessment type	Main neurological (N) and neuropsychiatric (NP) symptoms evaluated
		survivors 1 year after discharge and reveal related risk factors	52 weeks (12 months) after hospital discharge	Age: 50.8 ±14.4 years	BMI ≥ 23 (<i>n</i> = 221) BMI 18.5–22.9 (<i>n</i> = 295)	Questionnaire, General Anxiety Disorder-7 scale, Patient Health Questionnaire (PHQ)- 9, PSQI	
Miyazato, Y. <i>et al.,</i> 2022 [43]	Japan	To explore the factors involved in PCC development in a cohort of patients recovering from COVID-19 at a hospital in Japan	Cross- sectional; 35.5 weeks after symptom onset or COVID-19 diagnosis	Mixed population ^b ; n = 457 (male = 226) Age: 47 (IQR: 39– 55 years)	BMI as continuous variable	Online survey Self-reported BMI Questionnaire with list of symptoms	N: Smell and taste disorders
Moy, F.M. <i>et</i> <i>al.</i> , 2022 [40]	Malaysia	To investigate mental health status in the form of depression among COVID-19 survivors and its associated factors	Cross- sectional; 27.3 weeks after COVID- 19 infection	Mixed population ^b Sample of interest / study sample n = 567/732 (male = 302) Age: 40.2 \pm 10.9 years	Overweight/obe se $(n = 315)$ Normal weight /underweight $(n = 246)$	Online survey Reported BMI PHQ-9	NP: Depression
Shang, L. <i>et</i> <i>al.</i> , 2021 ^d [33]	China	To determine whether obesity has a long-term impact on COVID-19 recovery	Cohort; 46.1 weeks after hospital discharge	Hospitalized n = 118 (male = 48) Age: 53.0 (IQR: 44-61 years)	Obesity $(n = 53)$ Non-obesity $(n = 65)$	In-person interview Measured BMI Questionnaire	N: Smell disorder NP: sleep disturbance

Author, Year	Country	Study aim	Study design; Follow-up ^a	Study population	Categories of nutritional status	Assessment type	Main neurological (N) and neuropsychiatric (NP) symptoms evaluated
Sørensen, A.I.V, <i>et al.</i> , 2022 [45]	Denmark	To estimate the risk difference between COVID-19 positive and negative individuals; to evaluate the duration of symptoms; to explore the influence of risk factors on persistent symptoms	Cross- sectional; 38 weeks after COVID-19 test.	Mixed populaiton ^b (96% of outpatient) Sample of interest / study sample n = 61,002/152,880 (male = 25,172) Age: 49.0 (IQR: 39–60 years)	Obese $(n = 9,950)$ Overweight $(n = 19,264)$ Normal weight $(n = 25,285)$	Online survey and electronic records Self-reported BMI Web-based questionnaire	N: Headache, smell disorder, taste disorder, vertigo
Van-Wijhe, M. <i>et al.,</i> 2022 [46]	Denmark	To investigate the occurrence and risk factors for long- COVID symptoms and health-related quality of life	Cross- sectional; 12 weeks after positive PCR test	Outpatient Sample of interest / study sample n = 742/7420 (male = 245) Age: 48.2 ±15.0	Obesity $(n = 148)$ Overweight $(n = 226)$ Normal weight $(n = 368)$	Electronic patient records and online survey Questionnaire	N: Concentration issues, headache, memory issues, smell disorder, taste disorder, vertigo
Vassalini, P. <i>et al.</i> , 2021 [49]	Italy	To assess the prevalence of depressive symptoms and related risk factors at 3 months after hospitalization for COVID-19 infection	Cohort 12 weeks after hospital discharge	Hospitalized n = 115 (male = 62) Age: 47 (IQR: 48– 66 years)	Obesity $(n = 5)$ Non-obesity $(n = 110)$	Electronic medical records and telephone interviews PHQ-9	NP: Depression
Whitaker, M. <i>et al</i> , 2022 [47]	England	To estimate symptom prevalence; to investigate co-	Cross- sectional;	Mixed population ^b Sample of interest / study sample	Obesity (<i>n</i> = 18,892) Overweight (<i>n</i> = 27,986)	Survey (online/telephone) Self-reported BMI	N: Headache, memory issues, numbness, smell disorder, taste disorder, vertigo

_	Author, Year	Country	Study aim	Study design; Follow-up ^a	Study population	Categories of nutritional status	Assessment type	Main neurological (N) and neuropsychiatric (NP) symptoms evaluated
			occurrence of symptoms and assess risk factors for persistence of symptoms	12 weeks after symptom onset	n = 78,566/606,434 (male = 37,600) Age: 80% of sample between 25 and 65 years old	Normal weight $(n = 30,639)$	Questionnaire and self-reported symptoms	NP: sleep disturbance
256 257 258 259 260 261 262 263	^a Mean or me ^b Hospitalize ^c Argentina,	edian of follow-up d and outpatient; Brazil, Chile, Dor	polymerase chain reaction; IQ o time, in weeks; ninican Republic, Ecuador, M used to define excess weight	exico, Panama, Parag	uay, and Peru;			
264								
265								
266								
267								

268	Half of the studies[32, 33, 40, 43, 46, 50-52, 55] tested for differences in the
269	prevalence or risk of developing PCC neurological and neuropsychiatric symptoms based
270	on to nutritional status. One study found that BMI was inversely associated with the risk
271	of developing smell and taste disorders[43]. Positive associations between EW and
272	anxiety[32], depression[32, 40], and sleep disturbance[51, 52] were also reported, with
273	obesity being independently associated with sleep disturbance[51]. Table 2 displays data
274	on the frequency and risk of developing neurological and neuropsychiatric symptoms of
275	PCC from studies that examined differences between exposure and control groups. Other
276	studies[41, 42, 44, 45, 47–49, 53, 54] did not test for differences in the prevalence or risk
277	of specific persistent neuropsychiatric symptoms. Data on symptom frequency by
278	nutritional status are available in the supporting information (S2 Table).
279	
280	
281	
282	
283	
284	
285	
286	
287	
288	
289	
290	
291	
292	

Author, year	Frequency (%) of PCC Symptoms according to nutritional status			Significantly higher frequency of symptoms among exposure groups?	Effect measure of nutritional status on the risk/protection of developing a PCC symptom	Exposure increased the risk of symptoms?	
	ŀ	Excess Weight versi	us Normal Weight		-OD (050/ CD	(Veg / Ne)	
		Exposure groups	Control group	(Yes / No)	aOR (95%CI)	(Yes / No)	
Desgranges, F. <i>et al.</i> , 2022	Smell and taste disord Headache Loss of balance Memory issues Numbness Sleep disturbance	ders NA	NA	NA	1.01 (0.61-1.67); $p=0.96$ 0.79 (0.48-1.75); $p=0.79$ 1.46 (0.35-6.09); $p=0.61$ 1.79 (0.93-3.44); $p=0.08$ 2.74 (0.79-9.50); $p=0.11$ 2.08 (1.03-4.21); $p=0.04^*$	No No No No Yes	
Epsi, N.J. et al., 2024	Smell and taste disore	der 0.01	0.02	No	0.89 (0.37–2.12)	No	
Li, Z. <i>et al.</i> , 2023 ^a	Anxiety Depression Sleep disturbance	16.3 21.7 51.1	13.8; <i>p</i> =0.000* 19.0; <i>p</i> =0.052* 43.3; <i>p</i> =0.018*	Yes No Yes	NA	NA	
Miyazato, Y. et al., 2022	Smell disorder Taste disorder	NA	NA	NA	0.94 (0.89-0.99); <i>p</i> =0.014* 0.93 (0.88-0.98); <i>p</i> =0.012*	Yes Yes	
Moy, F.M. <i>et al.</i> , 2022	Depression	51.7	42.3; p=0.026*	Yes	1.83 (1.18-2.82)	Yes	
Van-Wijhe, M. <i>et al.</i> , 2022	Concentration issues Headache Memory impairment Taste disorder Smell disorder Vertigo	NA	NA	NA	1.01 (0.70-1.47) 1.09 (0.75-1.58) 0.94 (0.62-1.42) 0.85 (0.61-1.32) 0.72 (0.45-1.05) 0.95 (0.64-1.42)	No No No No No	

Table 2. Frequency of neuropsychiatric symptoms related to post-COVID condition and the risk of their development in included studies.

		Obesity vers	us Non-obesity	(Yes / No)	OD (05%/ CI)	(Yes / No)	
	Exposure groups		Control group	(1657110)	OR (95%CI)	(105/110)	
Chudzik, M. <i>et al</i> ., 2022	Smell and taste disorder	3.1	5.1	No	0.65 (0.35-1.22); <i>p</i> =0.185	No	
Epsi, N.J. <i>et</i> <i>al.</i> , 2024	Smell and taste disorder	0.01	0.02	No	0.76 (.29–1.99)	No	
	Ageusia	8.0	6.8	Yes	NA	NA	
	Anosmia	2.3	6.8	No	NA	NA	
Fernández-	Anxiety	15.9	9.7	Yes	1.75 (0.82-3.72); <i>p</i> = 0.146	No	
de- las-	Cognitive deficit	9.1	6.8	Yes	NA	NA	
Peñas, C. <i>et</i>	Concentration issues	13.6	9.1	Yes	NA	NA	
al, 2021	Depression	13.6	15.9	No	0.83 (0.40 - 1.73); p = 0.628	No	
ui, 2021	Headache	8.0	5.7	Yes	NA	NA	
	Memory impairment	18.2	14.8	Yes	NA	NA	
	Sleep disturbance	45.5	25.6	Yes	2.10 (1.13-3.83); <i>p</i> =0.020*	Yes	
Shang, L. et	Sleep disturbance	39.6	44.6; <i>p</i> = 0.590	No		274	
<i>al.</i> , 2021 ^a	Smell disorder	7.5	7.7; p = 0.970	No	NA	NA	
	Concentration issues				0.96 (0.62-1.49)	No	
Von Wiiho	Headache				1.06 (0.69-1.65)	No	
V 2n_W/11he	Memory impairment	NA	NA	NA	0.92 (0.56-1.50)	No	
	Taste disorder	INA	INA	INA	1.00 (0.65-1.55)	No	
	Smell disorder				0.83 (0.53-1.55)	No	
	Vertigo				0.90 (0.56-1.45)	No	

*Statistically significant; NA: non-available information; excess-weight group (BMI $\geq 25 \text{ kg/m}^2$); normal-weight group (BMI $\leq 25 \text{ kg/m}^2$); obesity group (BMI $\geq 30 \text{ kg/m}^2$); non-obesity group (BMI $\leq 30 \text{ kg/m}^2$). a Different cut-off values were used to define excess weight and obesity in Asian populations (excess weight $\geq 23 \text{ kg/m}^2$; obesity $\geq 25 \text{ kg/m}^2$).

293 Excess Weight and the Risk of Neuropsychiatric Symptoms

294	We assessed the risk ratios (RRs) for the EW group (Figs 3a and 3b). Excess
295	weight significantly increased the risk of depression (RR = 1.21; 95% CI: 1.03–1.42; I^2 =
296	0.00), headache (RR = 1.21; 95% CI: 1.09–1.35; I^2 = 41.3%), memory issues (RR = 1.43;
297	95% CI: 1.24–1.65; $l^2 = 0.00$), numbress (RR = 1.37; 95% CI: 1.24–1.51; $l^2 = 0.00$), sleep
298	disturbance (RR = 1.31; 95% CI: 1.16–1.48; I^2 = 17.83), taste disorder (RR = 1.11; 95%
299	CI: 1.00–1.23; $l^2 = 53.46$), and vertigo (RR = 1.21; 95% CI: 1.04–1.41; $l^2 = 0.00$). No
300	significant association was found between EW and other evaluated symptoms (S1 Figs
301	1a and 1b).
302	
303	Fig 3a. Forest plots of excess weight and risk ratio (RR) for neurological and
	The survey plots of excess weight and this futio (RRC) for neurological and
304	neuropsychiatric symptoms. ^a Applied a different cut-off of BMI. Excess weight > 23kg/m ² .
304	neuropsychiatric symptoms. ^a Applied a different cut-off of BMI. Excess weight > 23kg/m ² .
304 305	neuropsychiatric symptoms. ^a Applied a different cut-off of BMI. Excess weight > 23kg/m ² . Fig 3b; Forest plots of excess weight and risk ratio (RR) for neurological and
304305306	neuropsychiatric symptoms. ^a Applied a different cut-off of BMI. Excess weight > 23kg/m ² . Fig 3b; Forest plots of excess weight and risk ratio (RR) for neurological and
304305306307	neuropsychiatric symptoms. ^a Applied a different cut-off of BMI. Excess weight > 23kg/m ² . Fig 3b; Forest plots of excess weight and risk ratio (RR) for neurological and neuropsychiatric symptoms (Continuation).
 304 305 306 307 308 	neuropsychiatric symptoms. ^a Applied a different cut-off of BMI. Excess weight > 23kg/m ² . Fig 3b; Forest plots of excess weight and risk ratio (RR) for neurological and neuropsychiatric symptoms (Continuation). Four studies employed multivariate logistic regression and reported the risk of
 304 305 306 307 308 309 	neuropsychiatric symptoms. ^a Applied a different cut-off of BMI. Excess weight > 23kg/m ² . Fig 3b; Forest plots of excess weight and risk ratio (RR) for neurological and neuropsychiatric symptoms (Continuation). Four studies employed multivariate logistic regression and reported the risk of developing headache, smell disorder, memory impairment and taste disorder. These data

312 (OR 0.93; 95%CI 0.88-0.98; *P*=0,00). No significant associations were a
313 evaluated symptoms (S2 Fig 2).

314 **Obesity and the Risk of Neuropsychiatric Symptoms**

315 Our pooled risk analysis for obesity and neurological and neuropsychiatric 316 symptoms (Figs 4a and 4b) showed that individuals with obesity are at significantly

higher risk than those with normal weight or overweight (non-obesity control group) for a range of neurological symptoms: headache (RR = 1.41; 95% CI: 1.34–1.49; I^2 = 3.39); numbness (RR = 1.61; 95% CI: 1.46–1.78; I^2 = 0.00); smell disorder (RR = 1.15; 95% CI: 1.09–1.21; I^2 = 7.55); taste disorder (RR = 1.21; 95% CI: 1.07–1.36; I^2 = 63.57); and vertigo (RR = 1.44; 95% CI: 1.35–1.53; I^2 = 0.00). No statistically significant association was found between obesity and the risk of developing PCC-related neuropsychiatric symptoms (S1 Fig 1b).

324

Fig 4a. Forest plot of obesity and risk ratio (RR) for neurological and
 neuropsychiatric symptoms. ^a Applied a different BMI cut-off (obesity >25 kg/m²).

Fig 4b. Forest plot of obesity and risk ratio (RR) for neurological and
neuropsychiatric symptoms (continuation)

329

Substantial heterogeneity was observed in our meta-analysis for the nonsignificant association of obesity and anxiety ($I^2 = 70.5\%$) and sleep disorder ($I^2 = 61.94\%$) as well as for the statistically significant association between obesity and taste disorder ($I^2 = 69.5\%$). Meanwhile, no statistically significant heterogeneity was observed in other analyses where obesity was the exposure condition. Subgroup analyses could not be performed due to an insufficient number of studies evaluating the same outcome according to nutritional status.

337 Risk-of-bias Assessment and Publication Bias

We assessed the risk of bias for each effect measure (frequency and OR). Results for studies reporting the frequency of PCC symptoms are presented in Fig 5; while findings for studies reporting OR are displayed in Supporting Information (S3 Fig 3). Among the 18 studies evaluated, seven were judged to have a high risk of bias due to self-

342	reported exposure data[40, 43-45, 47, 52, 55]. The ROBINS-E tool indicated that no
343	further evaluation of a study was required for studies with inappropriate measurement of
344	exposure or outcome; therefore, this tool was applied only to the remaining 11 studies[32,
345	33, 41, 42, 46, 48–51, 53, 54].
346	Fig 5: Summary plot and traffic light plot illustrating the risk of bias in the included
347	studies, assessed using the ROBINS-E tool.
348	
349	The domain most affecting the assessment was control for confounders (Domain
350	1 [D1]). Few studies employed appropriate designs (e.g., randomization or matching)[46,
351	51, 54] or analytical methods (e.g., stratification)[32, 48-50]; only one study had an
352	overall low risk of bias[50]. Concerns were also noted regarding exposure measurement
353	(Domain 2 [D2]), particularly when data were obtained from electronic medical records
354	without reporting time-related information[51]. Visual assessment of the funnel plots did
355	not imply asymmetry.
356	Findings from the GRADE assessment are presented in Table 3 and supporting
357	information (S3 Table). The quality of evidence was downgraded from high to very low
358	for three outcomes (headache, taste disorder, and vertigo) due to high risk of bias,
359	imprecision of results, and publication bias. For the other outcomes, the quality of
360	evidence was rated as low, having been downgraded from high due to risk of bias and
361	publication bias.
362	

Table 3. Assessment of the overall certainty of the evidence.

	I I I Inconsistency I Indirectness I Imprec						No of p	oatients		Effect	
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Excess weight	normal weight	Relative (95% CI)	Absolute (95% CI)	Certainty
Depressi	on (follow-u	p: range 2	27 to 52 weeks;	assessed with: S	Scales)						
2	non- randomis ed studies	seriousª	not serious	not serious ^a	not serious	publication bias strongly suspected ^b	211/536 (39.4%)	160/541 (29.6%)	RR 1.21 (1.03 to 1.42)	62 more per 1000 (from 9 more to 124 more)	⊕⊕⊖⊖ Low ^{a,b}
Sleep dis	turbance (fo	ollow-up:	range 12 to 52 v	veeks; assessed	with: Question	naire and scales)					
6	non- randomis ed studies	serious ^a	not serious	not serious	not serious	publication bias strongly suspected ^b	3861/47 449 (8.1%)	1958/31 420 (6.2%)	RR 1.31 (1.16 to 1.48)	19 more per 1000 (from 10 more to 30 more)	⊕⊕⊖⊖ Low ^{a,b}
Headach	e (follow-up	: range 12	2 to 387 weeks;	assessed with: (Questionnaire a	and self-reported)	I				
7	non- randomis ed studies	serious ^a	not serious	not serious	serious ^c	publication bias strongly suspected ^b	4475/76 399 (5.9%)	2773/56 352 (4.9%)	RR 1.15 (1.07 to 1.22)	7 more per 1000 (from 3 more to 11 more)	⊕⊖⊖⊖ Very low ^{a,b,c}
Memory	issues (follo	w-up: rar	nge 12 to 32 wee	ks; assessed wi	th: Questionna	ire)					
3	non- randomis ed studies	seriousª	not serious	not serious	not serious	publication bias strongly suspected ^b	563/704 1 (8.0%)	267/483 1 (5.5%)	RR 1.43 (1.24 to 1.65)	24 more per 1000 (from 13 more to 36 more)	⊕⊕⊖⊖ Low ^{a,b}
Numbne	ss (follow-uj	p: range 1	2 to 32 weeks; a	ssessed with: Q	Questionnaire)		•			•	
3	non- randomis ed studies	serious ^a	not serious	not serious	not serious	publication bias strongly suspected ^b	1141/47 075 (2.4%)	550/309 59 (1.8%)	RR 1.37 (1.24 to 1.51)	7 more per 1000 (from 4 more to 9 more)	⊕⊕⊖⊖ Low ^{a,b}

			Certainty	assessment			No of p	oatients			
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Excess weight	normal weight	Relative (95% CI)	Absolute (95% CI)	Certainty
Taste dis	Taste disorder (follow-up: range 12 to 38 weeks; assessed with: Questionnaire and self-reported)										
5	non- randomis ed studies	serious ^a	not serious	not serious	serious ^{d,e}	publication bias strongly suspected ^b	4914/76 330 (6.4%)	3445/56 307 (6.1%)	RR 1.11 (1.00 to 1.23)	7 more per 1000 (from 0 fewer to 14 more)	⊕○○○ Very low ^{a,b,d}

Vertigo (follow-up: range 12 to 38 weeks; assessed with: Questionnaire and self-reported)

5	non-	serious ^a	not serious	not serious	serious ^f	publication bias	2795/76	1764/56	RR 1.21	7 more per 1000	⊕000
	randomis					strongly	348	282	(1.04 to	(from 1 more to 13	Very low ^{a,b,e}
	ed studies					suspected ^b	(3.7%)	(3.1%)	1.41)	more)	

CI: confidence interval; **RR**: risk ratio; a. The risk of bias of included studies is related to measurement of exposure (self-reported) or confounders control, especially regarding severity of COVID-19 acute phase; b. There are less than 10 studies included in the meta-analysis therefore we were unable to evaluate publication bias; c. Meta-analysis showed moderate heterogeneity among included studies ($I^2 = 41\%$); d. The quality of evidence was downgraded from high due to the high risk of bias of included studies; e. Meta-analysis showed moderate heterogeneity among included studies ($I^2 = 53\%$); f. Meta-analysis showed moderate heterogeneity among included studies ($I^2 = 59.5\%$).

364 **Discussion**

365 Although it has been suggested that individuals with increased BMI are at higher 366 risk of PCC, the associations between EW and specific PCC related neurological and 367 neuropsychiatric symptoms remained unclear. Our review reveals that EW is significantly 368 associated with a range of persistent and PCC symptoms, including headache, vertigo, 369 smell and taste disorder, sleep disturbance and depression. These findings suggest that 370 EW markedly increases the risk of developing these symptoms that persist for more than 371 12 weeks after COVID-19 onset. Moreover, this study is opportune as we transition into 372 the post-pandemic period facing the challenges of managing the co-occurrence of 373 pandemics, including overweight/obesity, mental health issues, and the burden of PCC.

374 Increased BMI has been identified as a determinant of adverse outcomes during both the acute and chronic phases of COVID-19[16, 24, 26]. This contrasts with the role 375 376 of sex in the disease course since the pattern of acute phase symptoms by sex is distinct 377 from that of PCC, which tends to affect more females[18, 56]. Additionally, the chronic 378 phase of COVID-19's has been variously defined, with some studies indicating symptoms 379 lasting for at least 4 weeks[10] and others extending to more than 12 weeks[5, 6]. 380 Differentiating these time frames is crucial to distinguish between acute illness and 381 potential sequelae of irreversible tissue damage, which may present with varying degrees 382 of impairment[57]. In our review, we used the cut-off criterion to ensure that we focused 383 on long-term or chronic outcomes of COVID-19. The mean follow-up time from illness 384 onset in the included studies was 25.8 weeks (ranging from 12 to 52 weeks). A large 385 systematic review[2] evaluated the prevalence of persistent symptoms among COVID-19 386 survivors at different follow-up periods. It identified sleep disorder and concentration 387 difficulties as the most common symptoms at 3–6 months (24%, 95% CI: 8%–44%; 22%, 388 95% CI: 15%–31%, respectively), with sleep disorder being most prevalent at over 12

months. However, unlike our results, this review had a high degree of between-study
heterogeneity and did not include BMI in subgroups analysis.

391 Long-term neurological symptoms significantly decrease the quality of life for 392 individuals, a situation that might be exacerbated by a pre-exiting comorbidities[58]. 393 Moreover, symptoms related to comorbidities often overlap with those of PCC, leading 394 individuals with obesity to attribute their symptoms to their metabolic disease rather than 395 to persistent manifestations of COVID-19[59, 60]. Additionally, overweight individuals 396 also report health complaints, including headache and sleeplessness, associated to their 397 subclinical disease state also known as suboptimal health status, which can be exacerbated 398 by PCC symptoms[20]. The co-occurrence of these complex conditions can have 399 deleterious effects, impairing people's daily functioning and increasing the demand on 400 healthcare systems. Our results highlight a significantly increased risk for persistent 401 headache, vertigo, numbness and taste disorder in individuals with EW or obesity. This 402 underscores the role of excessive body weight (fat deposits) in PCC. It is worth noting 403 that patients with PCC have reported that head pain worsens with physical exercise while 404 a decrease in physical activity coupled with increase in sedentary behaviour are generally 405 known to contribute to weight gain[61]¹[62]. Moreover, taste disorders may influence 406 unhealthy weight-related behaviours, such as consuming more palatable, ultra-processed 407 foods high in salt, sugar, and additives. These foods can further impair gustatory function 408 and exacerbate unhealthy symptoms[63, 64]. Vertigo which impairs daily functioning by 409 increasing the risk of falls may also be associated with depression[65, 66]. Therefore, 410 healthcare systems and public policies should focus on multidisciplinary rehabilitation 411 services to address the long-term impacts of COVID-19 on survivors, specifically through 412 concomitant personalized management of weight, neurological and neuropsychiatric 413 issues.

414 The high prevalence of persistent complex concurrent symptoms may create a 415 vicious circle between physical and neuropsychiatric symptoms, increasing the risk for 416 depression[67-70]. A significant positive association between obesity and depressed 417 mood has been observed across multiple COVID-19 periods, similar to findings in other 418 coronavirus outbreaks[9, 14, 62]. During the COVID-19 pandemic, a systematic review 419 of longitudinal studies identified obesity/overweight as a risk factor for depression 420 (pooled RR = 1.2; 95% CI: 1.11-1.31). However, no significant association was found 421 when obesity/overweight was self-reported (pooled RR = 1.03; 95% CI: 0.99–1.26)[71]. 422 In this study, we observed a heightened risk of persistent depression among individuals 423 with EW compared with those with normal weight. This findings aligns with Aminian et 424 al.[72] who reported that the need for diagnostic test to assess neuropsychiatric problems 425 (a *proxy* for symptoms) was significantly higher in individuals with increased BMI 426 compared to those with normal weight. Although our pooled RR for EW and depression 427 included data from two studies conducted with Asian populations[32, 40] featuring 428 different BMI assessments (measured and self-reported) and BMI cut-offs (excess weight 429 defined as BMI ≥ 23 kg/m² and obesity as BMI ≥ 25 kg/m²), both studies used a validated 430 depression scale (PHQ-9), and the results were not heterogeneous.

431 It remains uncertain whether neurological and neuropsychiatric manifestations 432 related to PCC are directly attributable to the virus itself or if they develop indirectly 433 (such as, through an immune response or medical therapy). These symptoms may also 434 involve both the central and peripheral nervous systems[14]. Additionally, the role of EW 435 in the progression of COVID-19 is not fully understood, though it may be linked to an 436 exaggerated inflammatory response or shared pre-existing genetic factors that these 437 conditions share [73-75]. EW is also a recognized risk factor for various chronic 438 conditions and the number of pre-existing comorbidities has been associated to the

development of PCC symptoms up to two years after COVID-19 onset, in both
hospitalized and non-hospitalized patients[76]. Our results underscore the importance of
identifying at-risk individuals and highlight the need for timely personalized interventions
for COVID-19 survivors. These findings could inform the development of predictive and
preventive management plans for future waves of SARS-CoV-2 or other epidemics.

444 Our quality assessment results indicate that the included studies suffer from 445 methodological issues, particularly in measuring exposure. Studies that classified 446 individuals' nutritional status based on self-reported data were found to have a high risk 447 of bias, which contributed to downgrade in the overall quality of evidence of evaluated 448 for the evaluated symptoms. During the height of the pandemic, online health surveys 449 were often used when other research methods were infeasible[77]. However, significant 450 issues can also arise from self-reported symptoms in studies that did not employ 451 structured questionnaire or validated scales. Although screening tools have been proposed 452 to identify people with PCC they often do not consider neuropsychiatric symptoms[78] 453 or important cognitive symptoms[79] that significantly affect individuals' quality of life. 454 The observed moderate heterogeneity among studies evaluating headache, taste disorder 455 and vertigo has led to imprecision in the results and the limited number of studies included 456 in meta-analysis unable the assessment of publication bias, further contributing to 457 downgrade of the overall quality of evidence for those outcomes from high to very low.

It is important to acknowledge certain limitations when interpreting the findings of our research. Most of the included studies were cross-sectional which limits the ability to determine cause and effect relationships. The inconsistency in naming PCC symptoms among studies resulted in a relatively low number of studies reporting the same symptom which also precluded subgroup comparisons between hospitalized and outpatient populations. We included studies that used non-validated questionnaires to assess

464 symptoms, as it was necessary given that PCC is an emerging condition and validated 465 screening tools have vet to be developed. Although the cut-off for study inclusion 466 regarding time to follow-up (i.e., >12 weeks) allowed us to track long-term outcomes 467 from COVID-19 and address a gap in the literature, the follow-up period ranged from 12 468 to 52 weeks post-infection, the varying risk of PCC symptoms throughout different 469 follow-up periods was not investigated in subgroup analysis due to limited number of 470 studies. Additionally, the inclusion of both obesity and non-obesity as comparisons 471 groups led to the interchange of overweight individuals between exposure and control 472 groups. Nevertheless, defining EW and obesity as exposure groups was crucial given the 473 syndemic context. This approach enabled the evaluation of the risk of developing 474 persistent symptoms among different levels of excessive fat and highlighted that both 475 suboptimal health status (overweight) and illness (obesity) predisposed individuals to 476 PCC-related neuro-symptoms. However, the inherent differences among these groups 477 should be considered in health, disease prevention and diagnoses. Furthermore, the issues 478 related to body fat assessment should be noted as BMI remains the most widely used 479 screening tool for measuring adiposity. Although it is a simple and non-invasive measure 480 often related to the gold standard fat assessment BMI does not accounts for the types or 481 distribution of adipose tissue, nor does it for age and ethnic backgrounds[80]. Future 482 research should focus on longitudinal evaluation of COVID-19 survivors incorporating 483 objective assessment of symptoms and adiposity.

484 Despite these limitations, our review has several scientific and clinical strengths. 485 Notably, the number of investigated outcomes allowed for a pioneering evaluation of the 486 association of EW with both the physical and psychological long-term manifestations of 487 COVID-19. Additionally, the comprehensive definition of PCC that we applied during 488 our article search (to account for varied terminology), along with the inclusion of each

489 neurological and neuropsychiatric symptom specified in our search strategy, ensured a 490 thorough screening process. We also underscored the importance of addressing EW as a 491 global health concern, given its interplay with neurological and neuropsychiatric 492 manifestations, and infectious diseases such as COVID-19. The management of EW 493 should be considered in the treatment of neurological and neuropsychiatric symptoms due 494 to the significant impact that these combined conditions have on individuals' health.

495

496 **Conclusions**

497 Our systematic review and meta-analysis demonstrate that EW is significantly 498 associated with an increased risk of developing post-COVID-19 neurological and 499 neuropsychiatric symptoms, including headache, memory issues, numbness, smell and 500 taste disorders, vertigo, depression, and sleep disturbance. These findings underscore the 501 need for developing multidisciplinary rehabilitative strategies tailored to individual needs 502 to improve care management and support the overall health of affected individuals. Our 503 results provide evidence-based guidance for healthcare professionals and policymakers 504 in managing PCC, and further support ongoing global efforts to understand its underlying 505 mechanisms, epidemiology, and identification.

506

507 Acknowledgements:

We would like to thank the researchers who shared information and enabled more precise results in this study. We would also like to acknowledge students and collaborators of the PENSA research group at the University of Brasília and the Centre for Precision Health at Edith Cowan University for their support.

513 **References**

- 514 [1] Blumenthal D, Fowler EJ, Abrams M, Collins SR. Covid-19 Implications for 515 the Health Care System. *N Engl J Med* 2020; 383: 1483–1488.
- Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al.
 Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. *Clin Microbiol Infect* 2022; 28:
 657–666.
- [3] Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al.
 Post-acute COVID-19 syndrome. *Nat Med* 2021; 27: 601–615.
- 522 [4] Carfi A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute 523 COVID-19. *JAMA* 2020; 324: 603–605.
- 524 [5] WHO. A clinical case definition of post-COVID-19 condition by a Delphi
 525 consensus The Lancet Infectious Diseases,
 526 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00703527 9/fulltext (accessed 15 October 2023).
- 528[6]NICE NI for H and C of E. 1 Identification | COVID-19 rapid guideline: managing529the long-term effects of COVID-19 | Guidance | NICE,530https://www.nice.org.uk/guidance/ng188/chapter/1-Identification (2020, accessed53120 June 2024).
- 532 [7] Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-333 acute covid-19 in primary care. *BMJ* 2020; 370: m3026.
- 534 [8] Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, 535 mechanisms and recommendations. *Nat Rev Microbiol* 2023; 21: 133–146.
- [9] Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al.
 Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry* 2020; 7: 611–627.
- 540 [10] Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute 541 sequelae of COVID-19. *Nature* 2021; 594: 259–264.
- 542 [11] Fanshawe JB, Sargent BF, Badenoch JB, Saini A, Watson CJ, Pokrovskaya A, et
 543 al. Cognitive domains affected post-COVID-19; a systematic review and meta544 analysis. *Eur J Neurol*; n/a: e16181.
- 545 [12] Badenoch JB, Rengasamy ER, Watson C, Jansen K, Chakraborty S, Sundaram RD,
 546 et al. Persistent neuropsychiatric symptoms after COVID-19: a systematic review
 547 and meta-analysis. *Brain Commun* 2022; 4: fcab297.
- 548 [13] Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute
 549 COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)—A
 550 systematic review and meta-analysis. *J Med Virol* 2022; 94: 253–262.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.20.24317635; this version posted November 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- 551 Pilotto A, Cristillo V, Cotti Piccinelli S, Zoppi N, Bonzi G, Sattin D, et al. Long-[14] 552 term neurological manifestations of COVID-19: prevalence and predictive factors. 553 Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 2021; 42: 4903–4907.
- 554 Luo D, Mei B, Wang P, Li X, Chen X, Wei G, et al. Prevalence and risk factors for [15] 555 persistent symptoms after COVID-19: a systematic review and meta-analysis. Clin 556 Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2024; 30: 328–335.
- 557 [16] Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et 558 al. Risk Factors Associated With Post-COVID-19 Condition: A Systematic 559 Review and Meta-analysis. JAMA Intern Med 2023; 183: 566-580.
- 560 Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive [17] 561 impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. 562 Brain Behav Immun 2022; 101: 93–135.
- 563 Notarte KI, de Oliveira MHS, Peligro PJ, Velasco JV, Macaranas I, Ver AT, et al. [18] 564 Age, Sex and Previous Comorbidities as Risk Factors Not Associated with SARS-565 CoV-2 Infection for Long COVID-19: A Systematic Review and Meta-Analysis. J 566 *Clin Med* 2022; 11: 7314.
- 567 Bray G a., Kim K k., Wilding J p. h., Federation on behalf of the WO. Obesity: a [19] 568 chronic relapsing progressive disease process. A position statement of the World 569 Obesity Federation. Obes Rev 2017; 18: 715–723.
- 570 [20] Mahara G, Tan X, Wang W. Risk Factors, Health Status, and Risk Groups in 571 Suboptimal Health Condition. In: Wang W (ed) All Around Suboptimal Health : 572 Advanced Approaches by Predictive, Preventive and Personalised Medicine for 573 Healthy Populations. Cham: Springer Nature Switzerland, pp. 61-72.
- 574 [21] Hepatology TLG&. Obesity: another ongoing pandemic. Lancet Gastroenterol 575 Hepatol 2021; 6: 411.
- 576 [22] Lockhart SM, O'Rahilly S. When Two Pandemics Meet: Why Is Obesity 577 Associated with Increased COVID-19 Mortality? Med N Y N 2020; 1: 33-42.
- 578 [23] Swinburn BA, Kraak VI, Allender S, Atkins VJ, Baker PI, Bogard JR, et al. The 579 Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet 580 Commission report. Lancet Lond Engl 2019; 393: 791-846.
- 581 [24] Nagar M, Geevarughese NM, Mishra R, Joshi A, Galwankar S, Yunus M, et al. 582 Body-mass index COVID-19 severity: A systematic review of systematic reviews. 583 J Fam Med Prim Care 2022; 11: 5351-5360.
- 584 [25] Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients 585 with COVID-19: a systematic review and meta-analysis of observational studies. 586 Anaesthesia 2020; 75: 1340–1349.
- 587 [26] Chen Z, Peng Y, Wu X, Pang B, Yang F, Zheng W, et al. Comorbidities and complications of COVID-19 associated with disease severity, progression, and 588 589 mortality in China with centralized isolation and hospitalization: A systematic 590 review and meta-analysis. Front Public Health 2022; 10: 923485.

- 591 [27] Staffolani S, Iencinella V, Cimatti M, Tavio M. Long COVID-19 syndrome as a 592 fourth phase of SARS-CoV-2 infection. *Infez Med* 2022; 30: 22–29.
- 593 [28] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.
 594 The PRISMA 2020 statement: an updated guideline for reporting systematic
 595 reviews. *The BMJ* 2021; 372: n71.
- 596 [29] McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS
 597 Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin
 598 Epidemiol 2016; 75: 40–46.
- 599 [30] Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and 600 mobile app for systematic reviews. *Syst Rev* 2016; 5: 210.
- [31] WHO Consultation on Obesity (1999: Geneva S, Organization WH. Obesity: preventing and managing the global epidemic: report of a WHO consultation.
 World Health Organization, https://iris.who.int/handle/10665/42330 (2000, accessed 12 June 2024).
- Li Z, He J, Wang Y, Bai M, Zhang Y, Chen H, et al. A cross-sectional study on the
 mental health of patients with COVID-19 1 year after discharge in Huanggang,
 China. *Eur Arch Psychiatry Clin Neurosci* 2023; 273: 301–310.
- 608 [33] Shang L, Wang L, Zhou F, Li J, Liu Y, Yang S. Long-term effects of obesity on
 609 COVID-19 patients discharged from hospital. *Immun Inflamm Dis* 2021; 9: 1678–
 610 1685.
- 611 [34] Higgins JPT, Morgan RL, Rooney AA, Taylor KW, Thayer KA, Silva RA, et al.
 612 A tool to assess risk of bias in non-randomized follow-up studies of exposure
 613 effects (ROBINS-E). *Environ Int* 2024; 186: 108602.
- [35] Ryan R, Hill S. How to GRADE the quality of the evidence. Cochrane Consumers
 and Communication Group, *Cochrane. Consumers and Communication*,
 https://cccrg.cochrane.org/author-resources (2016, accessed 8 November 2023).
- 617 [36] Schünemann HJ, Brożek J, Guyatt G, Oxman A. GRADE handbook,
 618 https://gdt.gradepro.org/app/handbook/handbook.html#h.h2a1ln3pqdrc (accessed
 619 18 June 2024).
- 620[37]GuidelineDevelopmentTool,621https://gdt.gradepro.org/app/#projects/p_l_deboraronca_gmail_com_0_lbcf9a94-62238f9-4870-ad7d-f19f0205fadc/evidence-syntheses/395b01fd-9923-48a0-81e7-623cf4c69f477d2/quality-of-evidence (accessed 18 June 2024).
- [38] DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;
 7: 177–188.
- [39] Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane
 Handbook for Systematic Reviews of Interventions,
 https://training.cochrane.org/handbook/current (accessed 12 June 2024).

- 629 [40] Moy FM, Lim ERJ, Hairi NN, Bulgiba A. Depression and its associated factors 630 among COVID-19 survivors in a middle income country. 2022; 631 2022.12.15.22283550.
- 632 [41] Gaur R, Asthana S, Yadav R, Ghuleliva R, Kumar D, Akhtar M, et al. Assessment 633 of Physical Disability After Three Months in Patients Recovered From COVID-19: A Cross-Sectional Study. Cureus; 14: e21618. 634
- 635 [42] Farhanah N, Charles Budiman, Muchlis Achsan Udji Sofro, Budi Riyanto, Suharyo 636 Hadisaputro, Muhammad Hussein Gasem. The Persistent Symptoms and Decreased Quality of Life of COVID-19 Patients (A 3-month Follow-up after 637 638 Discharge) Open Access Macedonian Journal of Medical Sciences, 639 https://oamjms.eu/index.php/mjms/article/view/9755 (2024, accessed 9 June 640 2024).
- 641 Miyazato Y, Tsuzuki S, Morioka S, Terada M, Kutsuna S, Saito S, et al. Factors [43] 642 associated with development and persistence of post-COVID conditions: A cross-643 sectional study. J Infect Chemother 2022; 28: 1242–1248.
- 644 [44] Alkwai HM, Khalifa AM, Ahmed AM, Alnajib AM, Alshammari KA, Alrashidi 645 MM, et al. Persistence of COVID-19 symptoms beyond 3 months and the delayed 646 return to the usual state of health in Saudi Arabia: A cross-sectional study. SAGE 647 Open Med 2022; 10: 20503121221129918.
- 648 [45] Sørensen AIV, Spiliopoulos L, Bager P, Nielsen NM, Hansen JV, Koch A, et al. A 649 nationwide questionnaire study of post-acute symptoms and health problems after 650 SARS-CoV-2 infection in Denmark. Nat Commun 2022; 13: 4213.
- 651 van Wijhe M, Fogh K, Ethelberg S, Karmark Iversen K, Nielsen H, Østergaard L, [46] 652 et al. Persistent Symptoms and Sequelae After Severe Acute Respiratory Syndrome 653 Coronavirus 2 Infection Not Requiring Hospitalization: Results From Testing Denmark, a Danish Cross-sectional Survey. Open Forum Infect Dis 2022; 10: 654 655 ofac679.
- 656 [47] Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. 657 Persistent COVID-19 symptoms in a community study of 606,434 people in 658 England. Nat Commun 2022; 13: 1957.
- 659 Bungenberg J, Humkamp K, Hohenfeld C, Rust MI, Ermis U, Dreher M, et al. [48] 660 Long COVID-19: Objectifying most self-reported neurological symptoms. Ann 661 *Clin Transl Neurol* 2022; 9: 141–154.
- 662 [49] Vassalini P, Serra R, Tarsitani L, Koukopoulos AE, Borrazzo C, Alessi F, et al. 663 Depressive Symptoms among Individuals Hospitalized with COVID-19: Three-664 Month Follow-Up. Brain Sci 2021; 11: 1175.
- 665 Chudzik M, Lewek J, Kapusta J, Banach M, Jankowski P, Bielecka-Dabrowa A. [50] 666 Predictors of Long COVID in Patients without Comorbidities: Data from the Polish 667 Long-COVID Cardiovascular (PoLoCOV-CVD) Study. J Clin Med 2022; 11: 4980. 668

perpetuity. It is made available under a CC-BY 4.0 International license .

- 669 [51] Fernández-de-las-Peñas C, Torres-Macho J, Elvira-Martínez CM,
 670 Molina-Trigueros LJ, Sebastián-Viana T, Hernández-Barrera V. Obesity is
 671 associated with a greater number of long-term post-COVID symptoms and poor
 672 sleep quality: A multicentre case-control study. *Int J Clin Pract* 2021; 75: e14917.
- [52] Desgranges F, Tadini E, Munting A, Regina J, Filippidis P, Viala B, et al.
 Post-COVID-19 Syndrome in Outpatients: a Cohort Study. *J Gen Intern Med* 2022;
 37: 1943–1952.
- 676 [53] Blümel JE, Vallejo MS, Bencosme A, Calle A, Dextre M, Díaz K, et al. Post677 COVID-19 syndrome in a sample of climacteric women living in Latin America.
 678 *Menopause N Y N* 2023; 30: 165–173.
- [54] Carter SJ, Baranauskas MN, Raglin JS, Pescosolido BA, Perry BL. Functional
 Status, Mood State, and Physical Activity Among Women With Post-Acute
 COVID-19 Syndrome. *Int J Public Health* 2022; 67: 1604589.
- [55] Epsi NJ, Chenoweth JG, Blair PW, Lindholm DA, Ganesan A, Lalani T, et al.
 Precision Symptom Phenotyping Identifies Early Clinical and Proteomic
 Predictors of Distinct COVID-19 Sequelae. *J Infect Dis* 2024; jiae318.
- 685 [56] Global Burden of Disease Long COVID Collaborators, Wulf Hanson S, Abbafati
 686 C, Aerts JG, Al-Aly Z, Ashbaugh C, et al. Estimated Global Proportions of
 687 Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters
 688 Following Symptomatic COVID-19 in 2020 and 2021. *JAMA* 2022; 328: 1604–
 689 1615.
- [57] Lledó GM, Sellares J, Brotons C, Sans M, Antón JD, Blanco J, et al. Post-acute
 COVID-19 syndrome: a new tsunami requiring a universal case definition. *Clin Microbiol Infect* 2022; 28: 315–318.
- [58] Quan M, Wang X, Gong M, Wang Q, Li Y, Jia J. Post-COVID cognitive dysfunction: current status and research recommendations for high risk population. *Lancet Reg Health West Pac*; 38. Epub ahead of print 1 September 2023. DOI: 10.1016/j.lanwpc.2023.100836.
- Mansell V, Dykgraaf SH, Kidd M, Goodyear-Smith F. Long COVID and older
 people. *Lancet Healthy Longev* 2022; 3: e849–e854.
- [60] Wilk P, Stranges S, Cuschieri S. Does sex modify the effect of pre-pandemic body
 mass index on the risk of Long COVID? Evidence from the longitudinal analysis
 of the Survey of Health, Ageing and Retirement in Europe. *Int J Obes 2005* 2024;
 48: 821–829.
- Tana C, Giamberardino MA, Martelletti P. Long COVID and especially headache
 syndromes. *Curr Opin Neurol* 2023; 36: 168.
- [62] Melamed OC, Selby P, Taylor VH. Mental Health and Obesity During the COVID19 Pandemic. *Curr Obes Rep* 2022; 11: 23–31.

- 707 Avila C, Holloway AC, Hahn MK, Morrison KM, Restivo M, Anglin R, et al. An [63] 708 Overview of Links Between Obesity and Mental Health. Curr Obes Rep 2015; 4: 709 303-310.
- 710 [64] Contreras-Rodriguez O, Solanas M, Escorihuela RM, Dissecting ultra-processed 711 foods and drinks: Do they have a potential to impact the brain? Rev Endocr Metab 712 Disord 2022; 23: 697-717.
- 713 Gunes-Bayir A, Tandogan Z, Gedik-Toker Ö, Yabaci-Tak A, Dadak A. A [65] 714 Comparison Study of Nutritional Assessment, Diet and Physical Activity Habits, 715 Lifestyle and Socio-Demographic Characteristics in Individuals with and without Dizziness/Vertigo. Nutrients 2023; 15: 4055. 716
- 717 Neuhauser HK. The epidemiology of dizziness and vertigo. Handb Clin Neurol [66] 718 2016; 137: 67-82.
- 719 Hassan NM, Salim HS, Amaran S, Yunus NI, Yusof NA, Daud N, et al. Prevalence [67] 720 of mental health problems among children with long COVID: A systematic review 721 and meta-analysis. PLOS ONE 2023; 18: e0282538.
- 722 [68] Bourmistrova NW, Solomon T, Braude P, Strawbridge R, Carter B. Long-term 723 effects of COVID-19 on mental health: A systematic review. J Affect Disord 2022; 299: 118-125. 724
- 725 [69] Staples LG, Nielssen O, Dear BF, Bisby MA, Fisher A, Kayrouz R, et al. 726 Prevalence and Predictors of Long COVID in Patients Accessing a National Digital 727 Mental Health Service. Int J Environ Res Public Health 2023; 20: 6756.
- 728 [70] van der Feltz-Cornelis C, Turk F, Sweetman J, Khunti K, Gabbay M, Shepherd J, 729 et al. Prevalence of mental health conditions and brain fog in people with long 730 COVID: A systematic review and meta-analysis. Gen Hosp Psychiatry 2024; 88: 731 10-22.
- 732 Amiri S, Behnezhad S, Nadinlui KB. Body Mass Index (BMI) and risk of [71] 733 depression in adults: A systematic review and meta-analysis of longitudinal 734 studies. Obes Med 2018; 12: 1-12.
- 735 Aminian A, Bena J, Pantalone KM, Burguera B. Association of obesity with [72] 736 postacute sequelae of COVID-19. Diabetes Obes Metab 2021; 23: 2183–2188.
- N S, Ib M, Jjv M. Obesity Is a Risk Factor for Severe COVID-19 Infection: 737 [73] 738 Multiple Potential Mechanisms. Circulation; 142. Epub ahead of print 7 July 2020. 739 DOI: 10.1161/CIRCULATIONAHA.120.047659.
- 740 [74] McNeill JN, Lau ES, Paniagua SM, Liu EE, Wang JK, Bassett IV, et al. The role 741 of obesity in inflammatory markers in COVID-19 patients. Obes Res Clin Pract 742 2021; 15: 96-99.
- N A, My K, Pb M, Se P. Causal Inference for Genetic Obesity, Cardiometabolic 743 [75] 744 Profile and COVID-19 Susceptibility: A Mendelian Randomization Study. Front 745 Genet: Epub November 2020. 11. ahead of print 11 DOI: 746 10.3389/fgene.2020.586308.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.20.24317635; this version posted November 20, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 747 Fernández-de-las-Peñas C, Rodríguez-Jiménez J, Cancela-Cilleruelo I, Guerrero-[76] 748 Peral A, Martín-Guerrero JD, García-Azorín D, et al. Post-COVID-19 Symptoms 749 2 Years After SARS-CoV-2 Infection Among Hospitalized vs Nonhospitalized 750 Patients. JAMA Netw Open 2022; 5: e2242106.
- 751 Hlatshwako TG, Shah SJ, Kosana P, Adebayo E, Hendriks J, Larsson EC, et al. [77] Online health survey research during COVID-19. Lancet Digit Health 2021; 3: 752 753 e76–e77.
- 754 [78] Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. 755 Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA 2023; 329: 1934-1946. 756
- 757 [79] Burns G. Newcastle Post-COVID Syndrome Follow Up Screening Questionnaire, https://postcovidsyndromebsol.nhs.uk/images/Content/ 758 759 Newcastle post Covid Screening Tool.pdf. (accessed 12 July 2024).
- 760 Zhang X, Ha S, Lau HC-H, Yu J. Excess body weight: Novel insights into its roles [80] 761 in obesity comorbidities. Semin Cancer Biol 2023; 92: 16-27.

764 Supporting Information

- 765
- 766 S1 Table. Database search strategy.
- 767 S2 Table. Frequency of Post-COVID Condition neuropsychiatric symptoms of
- 768 included studies that did not test for statistical differences according to nutritional
- 769 status. Excess weight group (BMI ≥ 25 kg/m²); NW: Normal Weight group (BMI < 25kg/m²); Obesity
- 770 group (BMI \geq 30kg/m²); NOb: Non-obesity group (BMI < 30kg/m²).
- 771 S1 Fig 1a: Forest-plots of excess weight and neuropsychiatric symptoms (non-
- 772 significantly associations).
- 773 S1 Fig 1b. Forest-plots of obesity and neurological and neuropsychiatric symptoms
- 774 (non-significantly associations)
- S2 Fig 2. Forest-plot of the association of excess weight and the risk of neurological
 and neuropsychiatric symptoms.
- 777 S3 Fig 3. Traffic light plots of risk of bias of included studies that reported the risk
- 778 of developing neuro-symptoms assessed by Robbins-e tool.
- 779 S3 Table 3. Assessment of the overall certainty of the evidence for studies thar
- 780 compared the frequency of PCC neurological and neuropsychiatric symptoms
- among individuals with obesity and control groups

(a) Depression	Exces	ss weight	Norm	al weight			RR	Weight
Study	Symptom	No symptom	Symptom	No symptom			with 95% CI	(%)
Li, Z. et al., 2023	48	173	56	239		-	— 1.14 [0.81, 1.61]	21.66
Moy, F.M. et al., 2021	163	152	104	142		_	1.22 [1.02, 1.47]	78.34
Overall							1.21 [1.03, 1.42]	
Heterogeneity: T ² = 0.00	, I ² = 0.00%,	$H^2 = 1.00$						
Test of $\theta_i = \theta_j$: Q(1) = 0.1	l2, p = 0.73							
Test of medRxWpreprint doi:300s:// preprint (which was not ce	lonor 01012 01/2024 ertified by peer revie	ew) is the author/funder, w	sion posted Novembe ho has granted med	er 20, 2024. The copyrig Rxiv a license to display	ht holder for this the preprint in		_	
	It is made av	perpetuity. vailable under a CC-BY 4.0) International license	е.	0.8	1	1.6	

Random-effects DerSimonian-Laird model

(b) Sleep disturbance	Exces	ss weight	Norm	al weight				RR		Weight
Study	Symptom	No symptom	Symptom	No symptom	1			with 95%	CI	(%)
Alkwai, H.M. et al., 2022	3	29	14	167		_	_ .	1.21 [0.37,	3.98]	1.04
Gaur, R. et al., 2022	9	50	2	36				- 2.90 [0.66,	12.69]	0.68
Blümel, J.E. et al., 2022	4	161	3	136				1.12 [0.26,	4.93]	0.68
Farhanah, N. et al., 2022	0	41	2	61				0.30 [0.02,	6.19]	0.16
Li, Z. et al., 2023	113	108	128	167				1.18 [0.98,	1.42]	28.58
Whitaker, M. et al., 2022	3,711	43,167	1,780	28,859				1.36 [1.29,	1.44]	68.85
Overall							•	1.31 [1.16,	1 481	
Heterogeneity: T ² = 0.00, I ²	= 17.83%,	$H^2 = 1.22$					ľ			
Test of $\theta_i = \theta_j$: Q(5) = 4.27,	p = 0.51									
Test of θ = 0: z = 4.29, p =	0.00									
					0.0	0.1	1 8	_		
					0.0	0.1	1 0			

Random-effects REML model

(c) Headache	Exces	s weight	Norm	al weight				RR		Weight
Study	Symptom	No symptom	Symptom	No sympton	۱			with 95%	CI	(%)
Alkwai, H.M. et al., 2022	3	29	18	163		_		0.94 [0.29,	3.02]	0.79
Gaur, R. et al., 2022	3	56	1	37				- 1.93 [0.21,	17.90]	0.22
Blümel, J.E. et al., 2022	12	153	3	136		-		3.37 [0.97,	11.70]	0.69
Carter, S.J. et al., 2022	5	5	2	5		-	·	1.75 [0.47,	6.58]	0.61
Farhanah, N. et al., 2022	0	41	2	61				0.30 [0.02,	6.19]	0.12
Sørensen, A.I.V, et al., 2022	1,879	27,335	1,425	23,860				1.14 [1.07,	1.22]	48.49
Whitaker, M. et al., 2022	2,573	44,305	1,322	29,317				1.27 [1.19,	1.36]	49.07
Overall							•	1.21 [1.09,	1.35]	
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 4$	1.30%, H ² =	= 1.70								
Test of $\theta_i = \theta_j$: Q(6) = 9.29, p =	0.16									
Test of θ = 0: z = 3.64, p = 0.00)									
					0.0 0.0).1 1	8	-		

Figure 3a

(d) Memory issues RR Weight Excess weight Normal weight (%) Study Symptom No symptom Symptom No symptom with 95% CI 3 2.42 [0.66, 8.89] Alkwai, H.M. et al., 2022 29 174 1.19 7 Blümel, J.E. et al., 2022 158 134 7 5 1.18 [0.38, 3.63] 1.58 4,256 Whitaker, M. et al., 2022 553 6,291 255 1.43 [1.24, 1.65] 97.23 1.43 [1.24, 1.65] Overall Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$ Test of $\theta_i = \theta_j$: Q(2) = 0.75, p = 0.69 Test of θ = 0: z = 4.99, p = 0.00 0.5 2 8 1 4

Random-effects DerSimonian-Laird model

(e) Numbness

(e) Numbriess	Exces	ss weight	Norm	al weight					RR		Weight
Study	Symptom	No symptom	Symptom	No symptom					with 95%	CI	(%)
Alkwai, H.M. et al., 2022	1	31	5	176			_		— 1.13 [0.14,	9.37]	0.23
Blümel, J.E. et al., 2022	2	163	3	136			+		0.56 [0.10,	3.31]	0.32
medRxiy preprint doi: https://doi.or Whitakepreprint Orbien was wise riffi	rg/10.1101/2024.11. ed by peer review)	20.24317635: this versior is the author/funder, who perpetuity.	n posted November 2 has granted medRx	20, 2024. The copyright h iv a license to display the	older for this preprint in			I	1.37 [1.24,	1.52]	99.45
Overall	It is made availa	able under a CC-BY 4.0 In	ternational license .				•		1.37 [1.24,	1.51]	
Heterogeneity: T ² = 0.00, I ²	= 0.00%, H	$l^2 = 1.00$									
Test of $\theta_i = \theta_j$: Q(2) = 1.00,	p = 0.61										
Test of θ = 0: z = 6.08, p =	0.00										
					0.1	0.5	1	2	8		

Random-effects DerSimonian-Laird model

(f) Taste disorder

(f) faste disorder	Exce	ss weight	Norm	al weight					RR	Weight
Study	Symptom	No symptom	Symptom	No symptom					with 95% CI	(%)
Alkwai, H.M. et al., 2022	1	31	14	167			_		0.40 [0.06, 2.97]	0.26
Blümel, J.E. et al., 2022	3	162	2	137					- 1.26 [0.21, 7.46]	0.33
Farhanah, N. et al., 2022	1	40	2	61					- 0.77 [0.07, 8.20]	0.18
Sørensen, A.I.V, et al., 2022	2,616	26,598	2,160	23,125			•		1.05 [0.99, 1.11]	51.45
Whitaker, M et al., 2022	2,293	44,585	1,267	29,372					1.18 [1.11, 1.26]	47.78
Overall							٠		1.11 [1.00, 1.23]	
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 53$	3.46%, H ² =	2.15								
Test of $\theta_i = \theta_j$: Q(4) = 8.60, p = 0	0.07									
Test of θ = 0: z = 1.98, p = 0.05										
					0.1	0.3	1	4		
Random-effects DerSimonian-La	aird model									

(g) Vertigo	Even	a uusiaht	Marrow	alusiaht					00		Maight
		ss weight		nal weight					RR		Weight
Study	Symptom	No symptom	Symptom	No symptom					with 95%	6 CI	(%)
Alkwai, H.M. et al., 2022	5	27	3	178			_		- 9.43 [2.37,	37.51]	1.19
Gaur, R. et al., 2022	0	59	1	37			_	-	0.22 [0.01,	5.18]	0.23
Blümel, J.E. et al., 2022	1	164	1	138			•		0.84 [0.05,	13.34]	0.30
Sørensen, A.I.V, et al., 2022	1,251	27,963	920	24,365			•		1.18 [1.08,	1.28]	49.09
Whitaker, M. et al., 2022	1,538	45,340	839	29,800			•		1.20 [1.10,	1.30]	49.19
Overall							•		1.21 [1.04,	1.41]	
Heterogeneity: $\tau^2 = 0.01$, $I^2 = 5$	59.53%, H ² =	2.47									
Test of $\theta_i = \theta_j$: Q(4) = 9.88, p =	0.04										
Test of θ = 0: z = 2.46, p = 0.0	1								_		
					0.0	0.1	1	8			

Random-effects DerSimonian-Laird model

Figure 3b

(a) Headach

(a) Headache	0	besity	Non	-obesity						RR		Weight
Study	Symptom	No symptom	Symptom	No symptom						with 95%	6 CI	(%)
Gaur, R. et al., 2022	2	30	2	63						-2.03 [0.30,	13.77]	0.08
Blümel, J.E. et al., 2022	4	37	11	252	-	-	•		_	2.33 [0.78,	6.98]	0.24
Carter, S.J. et al., 2022	2	2	5	8		·		_		1.30 [0.39,	4.30]	0.20
Fernández-de-las-Peñas, C. et al., 2021	7	81	10	166				-		1.40 [0.55,	3.55]	0.34
Sørensen, A.I.V, et al., 2022	773	9,177	2,531	42,018						1.37 [1.27,	1.48]	42.43
Whitaker, M. et al., 2022	1,239	17,653	2,656	55,969						1.45 [1.36,	1.55]	56.71
Overall						+				1.41 [1.34,	1.49]	
Heterogeneity: r ² = 0.00, I ² = 3.39%, H ² =	1.04											
Test of $\theta_i = \theta_j$: Q(5) = 2.17, p = 0.83												
Test of 0 = 0: z = 12.56, p = 0.00										_		
					0.5	1 :	2	4	8	_		

Weight (%)

0.87

5.83

Random-effects REML model

(b) Memory issues Obesity Non-obesity RR Symptom No symptom Symptom No symptom with 95% CI Study Blümel, J.E. et al., 2022 1.28 [0.29, 5.65] 2 39 10 253 Bungenberg, J. et al., 2022 24 1.57 [1.06, 2.31] 12.12 6 1 29 -Fernández-de-las-Peñas, C. et al., 2021 72 1.23 [0.70, 2.17] 26 150 16 285 2,531 821 1.09 [0.96, 1.24] 81.18 Whitaker, M. et al., 2022 8,016 1.15 [1.00, 1.32] Overall Heterogeneity: r² = 0.00, I² = 4.25%, H² = 1.04 Test of $\theta_i = \theta_j$: Q(3) = 3.13, p = 0.37 Test of θ = 0: z = 1.95, p = 0.05 0.5 1 2 4

Random-effects DerSimonian-Laird model

(c) Numbness	0	besity	Non	-obesity					RR		Weight
Study	Symptom	No symptom	Symptom	No symptom					with 95%	6 CI	(%)
Blümel, J.E. et al., 2022	0	41	5	258					- 0.57 [0.03,	10.15]	0.12
Whitaker, M. et al., 2022	574	18,318	1,106	57,519					1.61 [1.46,	1.78]	99.88
Overall							•		1.61 [1.46,	1.78]	
Heterogeneity: T ² = 0.00, I	² = 0.00%, H	$H^2 = 1.00$									
Test of $\theta_i = \theta_j$: Q(1) = 0.50	, p = 0.48										
Test of θ = 0: z = 9.37, p =	0.00								_		
					0.1	0.3	1	4	_		

Random-effects DerSimonian-Laird model

Figure 4a

(d) Smell disorder	It is made available unde	perpetuity. r a CC-BY 4.0 Intern	ational license.	-obesity					RR	Weight
Study		No symptom		No symptom					with 95% CI	(%)
Blümel, J.E. et al., 2022	5	36	24	239		_		1.	.34 [0.54, 3.3	1] 0.32
Fernández-de-las-Peñas, C. et al., 2	2021 2	86	12	164			+	0.	.33 [0.08, 1.4	6] 0.12
Shang, L. et al., 2021d	4	49	5	60	_		+	0.	.98 [0.28, 3.4	7] 0.16
Sørensen, A.I.V, et al., 2022	1,131	8,819	4,485	39,704				1.	12 [1.05, 1.1	9] 51.63
Whitaker, M et al., 2022	1,190	17,702	3,121	55,504				1.	.18 [1.11, 1.2	6] 47.77
Overall							+	1.	15 [1.09, 1.2	1]
Heterogeneity: r ² = 0.00, I ² = 7.55%,	, H ² = 1.08									
Test of $\theta_i = \theta_j$: Q(4) = 4.33, p = 0.36										
Test of θ = 0: z = 5.30, p = 0.00										
					0.1 0.3	0.5	1	2		

Random-effects DerSimonian-Laird model

(e) Taste disorder	Obesity		Non-obesity			RR	Weight
Study	Symptom No symptom		Symptom No symptom			with 95% CI	(%)
Blümel, J.E. et al., 2022	1	40	4	259			0.30
Fernández-de-las-Peñas, C. et al., 2021	7	81	12	164		1.17 [0.48, 2.86] 1.73
Sørensen, A.I.V, et al., 2022	958	8,992	3,818	40,731		1.12 [1.05, 1.20] 49.30
Whitaker, M et al., 2022	1,048	17,844	2,512	56,113		1.29 [1.21, 1.39	48.66
Overall					•	1.21 [1.07, 1.36	5]
Heterogeneity: $\tau^2 = 0.01$, $I^2 = 63.57\%$, H^2	= 2.74						
Test of $\theta_i = \theta_j$: Q(3) = 8.23, p = 0.04							
Test of 0 = 0: z = 3.06, p = 0.00							
					0.3 0.5 1 2 4 8	1	

Random-effects DerSimonian-Laird model

(f) Vertigo	Obesity		Non-obesity						RR		Weight
Study	Symptom	No symptom	Symptom	No symptom	۱			wit	95%	6 CI	(%)
Gaur, R. et al., 2022	0	32	1	64				0.67 [0.03,	15.92]	0.04
Blümel, J.E. et al., 2022	0	41	2	261	_			1.26 [0.06,	25.73]	0.04
Bungenberg, J. et al., 2022	0	7	2	41	_			1.10 [0.06,	20.84]	0.05
Sørensen, A.I.V, et al., 2022	521	9,429	1,650	42,899				1.41 [1.28,	1.56]	43.64
Whitaker, M. et al., 2022	760	18,132	1,617	57,008				1.46 [1.34,	1.59]	56.23
Overall							+	1.44 [1.35,	1.53]	
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0$.	.00%, H ² = 1	1.00									
Test of $\theta_i = \theta_j$: Q(4) = 0.49, p =	0.97										
Test of 0 = 0: z = 11.22, p = 0.0	0										
					0.03	0.25	1 2	16			

Random-effects DerSimonian-Laird model

Figure 4b




Figure 5




Figure 1




Figure 2